MCID: FLR002
MIFTS: 55

Filariasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Filariasis

MalaCards integrated aliases for Filariasis:

Name: Filariasis 12 73 58 54 44 15 70 32
Disease Due to Superfamily Filarioidea 12

Characteristics:

Orphanet epidemiological data:

58
filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1080
ICD9CM 34 125.9
MeSH 44 D005368
NCIt 50 C34611
SNOMED-CT 67 50342004
MESH via Orphanet 45 D005368
ICD10 via Orphanet 33 B74.0 B74.1 B74.2 more
UMLS via Orphanet 71 C0016085
Orphanet 58 ORPHA2034
UMLS 70 C0016085

Summaries for Filariasis

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves parasitic infection of the lymphatics and subcutaneous tissue by nematodes of the superfamily Filarioidea.

MalaCards based summary : Filariasis, also known as disease due to superfamily filarioidea, is related to filarial elephantiasis and elephantiasis. An important gene associated with Filariasis is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Doxycycline and Diethylcarbamazine have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and t cells, and related phenotypes are immune system and digestive/alimentary

Wikipedia : 73 Filariasis is a parasitic disease caused by an infection with roundworms of the Filarioidea type. These... more...

Related Diseases for Filariasis

Diseases related to Filariasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 918)
# Related Disease Score Top Affiliating Genes
1 filarial elephantiasis 32.8 TLR6 TLR4 TLR2 IL5 IL2 IL10
2 elephantiasis 32.6 IL5 IL10 FLT4
3 mansonelliasis 32.0 IL5 IL10 IFNG
4 onchocerciasis 31.9 IL5 IL2 IGHE CCL5
5 volvulus of midgut 31.3 IL5 CRP ALB
6 hypereosinophilic syndrome 31.0 IL5 IL2 IGHE IFNG CCL5
7 ascaris lumbricoides infection 30.7 IL6 IL5 IFNG
8 endomyocardial fibrosis 30.6 TNF IL5 IL10
9 lymphadenitis 30.6 TNF TLR4 IL10 IFNG CRP
10 strongyloidiasis 30.6 IL5 IGHE IFNG
11 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.6 IL10 IFNG CTLA4
12 japanese encephalitis 30.5 TNF IL2 CCL5
13 dengue disease 30.4 TNF IL10 IFNG CCL5
14 encephalitis 30.4 TNF TLR2 IL6 IL10 CCL5
15 parasitic helminthiasis infectious disease 30.3 TNF TLR4 TLR2 IL6 IL5 IL2
16 chikungunya 30.3 TNF IL6 CCL5
17 schistosomiasis 30.3 TNF IL5 IL2 IL10 IGHE IFNG
18 orchitis 30.3 TNF IL6 IL2 IL10 CRP
19 yellow fever 30.2 IL6 IL5 CRP CCL5
20 lymphangioma 30.2 VEGFA IFNG FLT4
21 poliomyelitis 30.2 TNF IL10 IFNG
22 severe combined immunodeficiency 30.2 VEGFA IL6 IL2 IL10 IFNG
23 trypanosomiasis 30.2 TNF TLR9 IL6 IL10 IFNG ALB
24 cysticercosis 30.2 TLR4 IL6 IL5 IL10 IGHE
25 toxocariasis 30.2 IL5 IL10 IGHE CRP
26 trachoma 30.1 VEGFA TNF IL6 IL10
27 leishmaniasis 30.1 TNF TLR9 TLR4 TLR2 IL6 IL5
28 cystic echinococcosis 30.0 TLR4 TLR2 IL6 IL10 IFNG
29 ige responsiveness, atopic 30.0 IL5 IL10 IGHE IFNG
30 nephrotic syndrome 30.0 TNF IL6 IL2 CRP ALB
31 intestinal schistosomiasis 30.0 TNF IL5 IL2 IL10
32 mastitis 30.0 TLR2 IL6 CCL5 ALB
33 fascioliasis 29.9 IL10 IFNG ALB
34 echinococcosis 29.9 TNF TLR4 TLR2 IL6 IL5 IL10
35 rheumatic heart disease 29.9 TNF TLR2 IL6 IL10
36 amebiasis 29.9 TNF TLR2 IL10 ALB
37 trichomoniasis 29.9 TNF IL6 IL2 IL10
38 protein-energy malnutrition 29.9 TNF IL6 ALB
39 urinary schistosomiasis 29.9 IL5 IL10 IGHE IFNG CTLA4
40 pericardial effusion 29.9 VEGFA IL6 CRP ALB
41 arthropathy 29.9 TNF IL6 IFNG CRP
42 systemic autoimmune disease 29.9 IL6 CRP
43 tracheitis 29.8 TNF IL6 CRP
44 tenosynovitis 29.8 TNF IL6 CRP
45 cellulitis 29.8 TNF IL6 IL5 FLT4 CRP ALB
46 pulmonary hypertension 29.8 VEGFA TNF IL6 CRP ALB
47 fasciitis 29.8 TNF IL6 IL2 IFNG
48 taeniasis 29.8 TNF IL6 IL5 IL2 IL10 ALB
49 lepromatous leprosy 29.8 TNF TLR2 IL2 IL10 IFNG
50 uveitis 29.8 TNF IL6 IL2 IL10 IFNG CTLA4

Graphical network of the top 20 diseases related to Filariasis:



Diseases related to Filariasis

Symptoms & Phenotypes for Filariasis

MGI Mouse Phenotypes related to Filariasis:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.45 ALB CCL5 CHIT1 CRP CTLA4 FLT4
2 digestive/alimentary MP:0005381 10.37 ALB CTLA4 FLT4 FOXC2 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.37 ALB CRP CTLA4 FLT4 FOXC2 IFNG
4 hematopoietic system MP:0005397 10.36 CCL5 CTLA4 IFNG IL10 IL2 IL5
5 cardiovascular system MP:0005385 10.35 ALB CRP CTLA4 FLT4 FOXC2 IFNG
6 liver/biliary system MP:0005370 10.25 ALB CTLA4 FLT4 FOXC2 IFNG IL10
7 integument MP:0010771 10.11 CTLA4 FLT4 IFNG IL10 IL6 TLR2
8 muscle MP:0005369 10.1 ALB FLT4 FOXC2 IFNG IL10 IL6
9 neoplasm MP:0002006 10.07 ALB IFNG IL10 IL2 IL5 IL6
10 normal MP:0002873 9.91 ALB CTLA4 FLT4 FOXC2 IFNG IL10
11 no phenotypic analysis MP:0003012 9.87 FLT4 FOXC2 IFNG IL10 IL2 TNF
12 renal/urinary system MP:0005367 9.76 ALB FOXC2 IFNG IL6 TLR2 TLR4
13 reproductive system MP:0005389 9.65 FLT4 IFNG IL10 IL2 IL5 IL6
14 respiratory system MP:0005388 9.36 CTLA4 FOXC2 IFNG IL10 IL2 IL5

Drugs & Therapeutics for Filariasis

Drugs for Filariasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
2
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052
3
Sodium citrate Approved, Investigational Phase 3 68-04-2
4
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
5 Antimalarials Phase 3
6 Milbemycin Phase 3
7 Citrate Phase 3
8
Praziquantel Approved, Investigational, Vet_approved Phase 1 55268-74-1 4891
9
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
10 Pharmaceutical Solutions Phase 1
11 Toltrazuril Phase 1
12
Permethrin Approved, Investigational 52645-53-1 40326
13
Piperazine Approved, Vet_approved 110-85-0 4837
14
Mebendazole Approved, Vet_approved 31431-39-7 4030
15 Liver Extracts
16 Chelating Agents
17 Anticoagulants
18 DMP 777 157341-41-8
19 Piperazine citrate
20 Calcium, Dietary
21
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
2 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
3 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
4 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
5 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
6 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
7 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02927496 Phase 3 Doxycycline;Placebo
8 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02929134 Phase 3 Doxycycline;Placebo
9 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) DeWorm3 Project Recruiting NCT03014167 Phase 3 Albendazole
10 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
11 A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis Enrolling by invitation NCT04410406 Phase 3 Ivermectin;Diethylcarbamazine;Albendazole;Moxidectin
12 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
13 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
14 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
15 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
16 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
17 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
18 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) or matching placebo
19 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
20 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
21 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
22 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
23 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Completed NCT03352206 2 drug dose - DA;3 drug dose - IDA
24 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
25 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
26 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
27 Research for Elimination of Human Filariasis Completed NCT00145223
28 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual)
29 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
30 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
31 Exhaled NO Testing in Filariasis Completed NCT01628497
32 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
33 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
34 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
35 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
36 Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection Completed NCT00344279
37 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
38 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
39 Effect of Filarial Infection on Antigen-Specific Immune Responses in Latent Tuberculosis Completed NCT01547884
40 Host Response to Infection and Treatment in the Filarial Diseases of Humans Recruiting NCT00001230
41 When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to Recruiting NCT04124250
42 Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis Active, not recruiting NCT04258670
43 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Enrolling by invitation NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
44 Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study Terminated NCT01213576 Albendazole 400mg and ivermectin 200mcg/kg;Albendazole and ivermectin;Albendazole 400mg and ivermectin 200mcg/kg;albendazole 800mg and ivermectin 400mcg/kg bi-annually

Search NIH Clinical Center for Filariasis

Cochrane evidence based reviews: filariasis

Genetic Tests for Filariasis

Anatomical Context for Filariasis

MalaCards organs/tissues related to Filariasis:

40
Breast, Skin, T Cells, Liver, Eye, Lymph Node, Endothelial

Publications for Filariasis

Articles related to Filariasis:

(show top 50) (show all 6605)
# Title Authors PMID Year
1
Protective immunity in human filariasis: a role for parasite-specific IgA responses. 54 61
18588480 2008
2
Chitotriosidase deficiency is not associated with human hookworm infection in a Papua New Guinean population. 61 54
17765019 2007
3
IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. 61 54
16630955 2006
4
Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis. 54 61
15501755 2004
5
Polymorphisms of innate immunity genes and susceptibility to lymphatic filariasis. 54 61
14551607 2003
6
A four year follow up study of filaria specific IgE response in individuals with hydrocele. 61 54
11247197 2000
7
IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. 61 54
11138639 2000
8
Antigen-stimulated IL-4, IL-13 and IFN-gamma production by human T cells at a single-cell level. 61 54
9808184 1998
9
Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine chemotherapy. 61 54
7594718 1995
10
Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2. 61 54
7558279 1995
11
Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. 61 54
8473742 1993
12
Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans. 61 54
2112154 1990
13
The role of nuclear factor kappa B (NF-κB) in filarial pathology. 61
33630268 2021
14
Genome editing as control tool for filarial infections. 61
33581654 2021
15
A review on the interactions between dendritic cells, filarial parasite and parasite-derived molecules in regulating the host immune responses. 61
33247468 2021
16
[Physiopathology of vulvar elephantiasis of filarial origin. A case report]. 61
33726892 2021
17
Tiliacora racemosa leaves induce oxidative stress mediated DNA damage leading to G2/M phase arrest and apoptosis in cervical cancer cells SiHa. 61
33309918 2021
18
Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. 61
33370607 2021
19
High insecticide resistance mediated by different mechanisms in Culex quinquefasciatus populations from the city of Yaoundé, Cameroon. 61
33795804 2021
20
Community-directed distributors-The "foot soldiers" in the fight to control and eliminate neglected tropical diseases. 61
33661903 2021
21
Prevalence of scabies and impetigo in school-age children in Timor-Leste. 61
33722285 2021
22
A Draft Genome Assembly of Culex pipiens pallens (Diptera: Culicidae) Using PacBio Sequencing. 61
33501937 2021
23
Complex emergencies and the control and elimination of neglected tropical diseases in Africa: developing a practical approach for implementing safe and effective mapping and intervention strategies. 61
33789715 2021
24
The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso. 61
33647010 2021
25
[Abnormal urine color assessment: The urine wheel]. 61
33736891 2021
26
Delays in lymphatic filariasis elimination programmes due to COVID-19, and possible mitigation strategies. 61
33515454 2021
27
Immunization with Brugia malayi Calreticulin Protein Generates Robust Antiparasitic Immunity and Offers Protection during Experimental Lymphatic Filariasis. 61
33667079 2021
28
Semiannual Treatment of Albendazole Alone is Efficacious for Treatment of Lymphatic Filariasis: A Randomized Open-label Trial in Cote d'Ivoire. 61
33674871 2021
29
Corrigendum to: SUPPLEMENT, Two Decades of Public Health Achievements in Lymphatic Filariasis (2000-2020): Reflections, Progress and Future Challenges. 61
33749744 2021
30
Individual efficacy and community impact of ivermectin, diethylcarbamazine and albendazole mass drug administration for lymphatic filariasis control in Fiji: a cluster randomised trial. 61
33728462 2021
31
Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study. 61
33804133 2021
32
A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. 61
33657090 2021
33
Lymphatic filariasis, infection status in Culex quinquefasciatus and Anopheles species after six rounds of mass drug administration in Masasi District, Tanzania. 61
33648600 2021
34
An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. 61
33780481 2021
35
Monitoring migrant groups as a post-validation surveillance approach to contain the potential reemergence of lymphatic filariasis in Togo. 61
33653393 2021
36
Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor-mediated lymphangiogenesis. 61
33434186 2021
37
The use of molecular xenomonitoring for surveillance of mosquito-borne diseases. 61
33357052 2021
38
ASDB: A comprehensive omics database for Anopheles sinensis. 61
33588073 2021
39
New and sensitive HPLC-UV method for concomitant quantification of a combination of antifilariasis drugs in rat plasma and organs after simultaneous oral administration. 61
33527105 2021
40
Acidic Calcium-Independent Phospholipase A2 Regulates Eosinophil-Mediated Pathology during Filarial Manifestation of Tropical Pulmonary Eosinophilia. 61
33441441 2021
41
Human filariasis-contributions of the Litomosoides sigmodontis and Acanthocheilonema viteae animal model. 61
33547508 2021
42
Mapping the role of digital health technologies in the case detection, management, and treatment outcomes of neglected tropical diseases: a scoping review. 61
33618757 2021
43
Current Status and a Perspective of Mosquito-Borne Diseases in the Republic of Korea. 61
33136531 2021
44
A family-based intervention for prevention and self-management of disabilities due to leprosy, podoconiosis and lymphatic filariasis in Ethiopia: A proof of concept study. 61
33600453 2021
45
Optimizing Myanmar's community-delivered malaria volunteer model: a qualitative study of stakeholders' perspectives. 61
33557847 2021
46
The Eagle effect in the Wolbachia-worm symbiosis. 61
33627171 2021
47
A case of false identity: Primary cutaneous diffuse large B-cell lymphoma masquerading as Madura Foot. 61
33573513 2021
48
Lymphatic filariasis in Asia: a systematic review and meta-analysis. 61
33415391 2021
49
Filariasis of the breast caused by Brugia pahangi: A concomitant finding with invasive ductal carcinoma. 61
33027710 2021
50
High Tregs and systemic IL-10 expressions linked to the absence of sheath antibodies in lymphatic filariasis: implications on the persistence of residual infection. 61
33515426 2021

Variations for Filariasis

Expression for Filariasis

Search GEO for disease gene expression data for Filariasis.

Pathways for Filariasis

Pathways related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 VEGFA TNF TLR9 TLR6 TLR4 TLR2
2
Show member pathways
13.74 TNF TLR4 IL6 IL5 IL2 IL10
3
Show member pathways
13.63 VEGFA TNF IL6 IL5 IL2 IL10
4
Show member pathways
13.49 TNF TLR9 TLR6 TLR4 TLR2 TLR1
5
Show member pathways
13.47 VEGFA TNF IL6 IL5 IL2 IL10
6
Show member pathways
13.36 TNF IL6 IL5 IL2 IL10 FLT4
7
Show member pathways
13.31 TNF TLR9 TLR6 TLR4 TLR2 TLR1
8
Show member pathways
13.29 TNF TLR9 TLR6 TLR4 TLR2 TLR1
9
Show member pathways
13.1 VEGFA TNF TLR4 TLR2 IL6 IL2
10
Show member pathways
13.02 VEGFA TNF TLR4 TLR2 IL6 CCL5
11
Show member pathways
12.97 VEGFA TNF IL6 IL5 IL2 IL10
12
Show member pathways
12.95 TNF TLR9 TLR4 TLR2 IL6 IL2
13 12.93 VEGFA IL6 IL5 IL2 IFNG FLT4
14 12.9 TNF TLR9 TLR2 IL6 IFNG CCL5
15
Show member pathways
12.85 TNF TLR9 TLR6 TLR4 TLR2 IL6
16
Show member pathways
12.85 TNF TLR9 TLR6 TLR4 TLR2 TLR1
17
Show member pathways
12.81 TNF TLR9 TLR6 TLR4 TLR2 TLR1
18
Show member pathways
12.73 TNF TLR4 TLR2 IL6 IL5 IL2
19
Show member pathways
12.71 TNF TLR9 TLR6 TLR4 TLR2 TLR1
20
Show member pathways
12.7 TNF IL2 IL10 IGHE IFNG
21
Show member pathways
12.67 TNF IL6 IL2 IL10 IFNG
22
Show member pathways
12.67 TNF TLR9 TLR4 TLR2 IL6 IL5
23 12.62 TNF TLR9 TLR6 TLR2 TLR1 IL2
24
Show member pathways
12.54 VEGFA TLR9 TLR6 TLR4 TLR2 TLR1
25
Show member pathways
12.52 IL6 IL5 IL2 IL10 IFNG
26
Show member pathways
12.48 TNF IL6 IL2 IFNG CRP CCL5
27
Show member pathways
12.45 TNF TLR2 IL6 IL5 IFNG
28
Show member pathways
12.45 TNF IL6 IL2 IL10 CCL5
29
Show member pathways
12.4 TNF IL6 IL5 IL2 IL10 IFNG
30
Show member pathways
12.4 TNF TLR9 TLR6 TLR4 TLR2 TLR1
31
Show member pathways
12.38 TNF TLR4 TLR2 IL10 IFNG
32 12.37 VEGFA TNF TLR4 TLR2
33
Show member pathways
12.34 TNF TLR9 IL6 IL2 IL10
34 12.3 TNF TLR4 IL6 CCL5
35
Show member pathways
12.3 TNF TLR9 TLR6 TLR4 TLR2 TLR1
36 12.25 VEGFA TNF IL6 IL10
37 12.23 TNF TLR9 TLR6 TLR4 TLR2 TLR1
38 12.22 TNF TLR4 IL6 IL2 IL10
39 12.15 TNF TLR4 IL6 IL2 IFNG
40 12.15 TNF IL6 IL5 IL2 IL10 IFNG
41
Show member pathways
12.15 TLR9 TLR6 TLR4 TLR2 TLR1 IL5
42 12.13 VEGFA TNF IL6 IL10 IGHE
43 12.08 TNF TLR4 TLR2 IL6 IL10 IFNG
44 12.07 VEGFA TLR4 IL6 IFNG
45 12.03 VEGFA TNF TLR9 TLR6 TLR4 TLR2
46
Show member pathways
12 TLR9 TLR6 TLR4 TLR2 TLR1 IL6
47 11.98 TLR9 TLR6 TLR4 TLR2 TLR1
48 11.94 TNF IL5 IL2 IL10 IFNG
49 11.93 IL6 IL5 IL2 IFNG
50
Show member pathways
11.92 TNF IL5 IL2 IFNG CTLA4

GO Terms for Filariasis

Cellular components related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 VEGFA TNF IL6 IL5 IL2 IL10
2 extracellular region GO:0005576 9.47 VEGFA TNF TLR9 IL6 IL5 IL2
3 phagocytic vesicle membrane GO:0030670 9.43 TLR6 TLR2 TLR1
4 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.16 TLR2 TLR1

Biological processes related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.4 VEGFA TLR9 TLR6 TLR4 TLR2 TLR1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.3 VEGFA TNF TLR9 TLR4 TLR2 IL6
3 immune system process GO:0002376 10.25 TLR9 TLR6 TLR4 TLR2 TLR1 IL2
4 innate immune response GO:0045087 10.22 TLR9 TLR6 TLR4 TLR2 TLR1 IGHE
5 positive regulation of cell proliferation GO:0008284 10.21 VEGFA IL6 IL5 IL2 IFNG FLT4
6 negative regulation of apoptotic process GO:0043066 10.2 VEGFA IL6 IL2 IL10 FLT4 ALB
7 positive regulation of gene expression GO:0010628 10.16 VEGFA TNF TLR9 TLR6 TLR4 TLR2
8 defense response to bacterium GO:0042742 10.1 TNF TLR9 TLR6 TLR4 IL10 IGHE
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.09 VEGFA TNF TLR4 FLT4 CCL5
10 positive regulation of protein phosphorylation GO:0001934 10.09 VEGFA TNF IL2 IFNG FLT4
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.06 TNF TLR9 TLR6 TLR4 TLR2 IL6
12 cytokine-mediated signaling pathway GO:0019221 10.06 VEGFA TNF IL6 IL5 IL2 IL10
13 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.05 TNF TLR9 TLR6 TLR4
14 cellular response to lipopolysaccharide GO:0071222 10.04 TNF TLR4 IL6 IL10
15 positive regulation of MAPK cascade GO:0043410 10.02 VEGFA TLR9 IL6 FLT4
16 positive regulation of inflammatory response GO:0050729 10.02 TNF TLR9 TLR4 TLR2 IL2 IFNG
17 positive regulation of DNA-binding transcription factor activity GO:0051091 10.01 TNF IL6 IL5 IL10
18 defense response to Gram-positive bacterium GO:0050830 10.01 TNF TLR2 IL6 CRP
19 positive regulation of tumor necrosis factor production GO:0032760 10.01 TLR9 TLR4 TLR2 TLR1 IL6 IFNG
20 positive regulation of JNK cascade GO:0046330 9.99 TNF TLR9 TLR4 FLT4
21 regulation of insulin secretion GO:0050796 9.99 TNF IL6 IFNG CCL5
22 negative regulation of interleukin-6 production GO:0032715 9.98 TNF TLR9 TLR4 IL10
23 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.97 TNF TLR9 TLR4 TLR2
24 positive regulation of interferon-gamma production GO:0032729 9.97 TNF TLR9 TLR4 IL2
25 positive regulation of interleukin-1 beta production GO:0032731 9.96 TNF TLR4 IL6 IFNG
26 toll-like receptor signaling pathway GO:0002224 9.96 TLR9 TLR6 TLR4 TLR2 TLR1
27 positive regulation of endothelial cell proliferation GO:0001938 9.94 VEGFA IL10 FLT4
28 positive regulation of endothelial cell migration GO:0010595 9.94 VEGFA FOXC2 FLT4
29 response to glucocorticoid GO:0051384 9.94 TNF IL6 IL10
30 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.94 TNF TLR9 TLR4
31 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.94 VEGFA FOXC2 FLT4
32 positive regulation of T cell proliferation GO:0042102 9.93 IL6 IL2 CCL5
33 positive regulation of smooth muscle cell proliferation GO:0048661 9.93 TNF IL6 CCL5
34 humoral immune response GO:0006959 9.93 TNF IL6 IFNG
35 positive regulation of protein complex assembly GO:0031334 9.93 VEGFA TNF IFNG
36 positive regulation of nitric oxide biosynthetic process GO:0045429 9.93 TNF TLR6 TLR4 IFNG
37 positive regulation of cytokine production GO:0001819 9.92 TNF IL10 IFNG
38 positive regulation of cell adhesion GO:0045785 9.92 VEGFA TNF CCL5
39 negative regulation of interleukin-8 production GO:0032717 9.92 TLR9 TLR6 IL10
40 positive regulation of interleukin-12 production GO:0032735 9.92 TLR9 TLR4 TLR2 IFNG
41 positive regulation of JAK-STAT cascade GO:0046427 9.92 TNF IL6 IL5 IL10 CCL5
42 positive regulation of interferon-beta production GO:0032728 9.91 TLR9 TLR4 TLR2
43 positive regulation of B cell proliferation GO:0030890 9.91 TLR9 TLR4 IL5 IL2
44 positive regulation of interleukin-10 production GO:0032733 9.91 TLR9 TLR4 TLR2 IL6
45 lipopolysaccharide-mediated signaling pathway GO:0031663 9.9 TNF TLR4 TLR2 CCL5
46 positive regulation of JUN kinase activity GO:0043507 9.89 TNF TLR9 TLR6
47 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.89 TNF TLR6 TLR4 IL6
48 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.89 TLR9 TLR6 TLR4 TLR2 TLR1
49 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 VEGFA TNF IL6 IL2 IFNG CCL5
50 positive regulation of macrophage activation GO:0043032 9.87 TLR6 TLR4 IL10

Molecular functions related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.02 VEGFA TNF TLR6 TLR4 TLR2 TLR1
2 transmembrane signaling receptor activity GO:0004888 9.8 TLR9 TLR6 TLR4 TLR2 TLR1
3 signaling receptor activity GO:0038023 9.78 TLR6 TLR4 TLR2 TLR1
4 growth factor activity GO:0008083 9.77 VEGFA IL6 IL5 IL2 IL10
5 lipopolysaccharide receptor activity GO:0001875 9.46 TLR4 TLR2
6 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.46 TLR6 TLR4 TLR2 TLR1
7 Toll-like receptor 2 binding GO:0035663 9.43 TLR6 TLR1
8 lipopeptide binding GO:0071723 9.43 TLR6 TLR2 TLR1
9 NAD(P)+ nucleosidase activity GO:0050135 9.26 TLR6 TLR4 TLR2 TLR1
10 cytokine activity GO:0005125 9.23 VEGFA TNF IL6 IL5 IL2 IL10

Sources for Filariasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....